Issue Date: April 28, 2014 | Web Date: April 25, 2014
Pharma Firms Swap Assets
Novartisis exiting vaccines, GlaxoSmithKline is shedding oncology drugs, and Eli Lilly & Co. is boosting its animal health business through a suite of multi-billion-dollar transactions with each other. All told, the big pharma companies expect the swaps to strengthen their market positions at a time when all three are struggling to grow.
In the biggest transaction, Novartis will pay up to $16 billion to acquire GSK’s . . .
To view the rest of this content, please log in with your ACS ID.
- Chemical & Engineering News
- ISSN 0009-2347
- Copyright © American Chemical Society